OV
OVATF.US Ovation Science Inc
- Market cap
- USD 288K
- P/E
- -
- P/B
- 8.35x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is OVATF.US undervalued?
Graham numberThe Graham number of Ovation Science Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ovation Science Inc fundamental analysis
No fundamental analysis for Ovation Science Inc yet.
Ovation Science Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ovation Science Inc
Ovation Science Inc. engages in the production, sub-licensing, and sale of cannabis or hemp products in the United States. The company's patented skin delivery technology Invisicare, a patented polymer-based technology for topical and transdermal skin care products under the Ovation brand name. It also offers cannabis health and wellness products under the Invibe MD name; anti-aging products under the ARLO CBD name; and topical and transdermal creams and lotions with CBD, TH…
Full company profileOvation Science Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ovation Science Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 12.5K | 96.4K | 302K | 750K | 225K | 138K | 61.9K | 113K | 67.8K | 47.3K |
| Gross Profit | 30.1K | 82.5K | 284K | 548K | 188K | 135K | 54.1K | 85.7K | -312K | 47.2K |
| Operating Income | -51.1K | -413K | -834K | -935K | -1.52M | -739K | -695K | -479K | -598K | -530K |
| EBITDA | - | -52.6K | -832K | -1.16M | -1.52M | -787K | -779K | -404K | -598K | -530K |
| Net Income | -61.5K | -508K | -836K | -1.18M | -2.39M | -794K | -813K | -456K | -631K | -563K |
| EPS | 0.00 | -0.03 | -0.04 | -0.04 | -0.08 | -0.03 | -0.03 | -0.01 | -0.02 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 899K | 2.73M | 1.84M | 3.25M | 770K | 105K | 76.9K | 63.9K | 82.8K | 25.7K |
| Total Liabilities | 334K | 536K | 362K | 143K | 63.7K | 188K | 729K | 1.15M | 1.54M | 1.82M |
| Shareholders' Equity | 565K | 2.19M | 1.48M | 3.11M | 706K | -83.0K | -652K | -1.09M | -1.46M | -1.79M |
| Cash & Short-term Investments | 278K | 1.97M | 980K | 1.54M | 648K | 28.9K | 48.8K | 3.31K | 72.2K | 13.2K |
| Total Debt | 305K | 280K | 230K | - | - | 41.1K | 193K | 268K | 283K | 292K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -59.9K | -383K | -953K | -1.39M | -886K | -671K | -336K | -179K | -76.4K | -118K |
| Capital Expenditure | 317K | 31.7K | 31.7K | 135K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -377K | -383K | -985K | -1.52M | -886K | -671K | -336K | -179K | -76.4K | -118K |
| Ratios | ||||||||||
| ROE | -10.9% | -23.2% | -56.6% | -38.1% | -339.0% | - | - | - | - | - |
| ROA | -6.8% | -18.7% | -45.4% | -36.4% | -310.9% | -757.1% | -1,057.6% | -713.9% | -762.2% | -2,190.0% |
| Net Profit Margin | -490.6% | -527.3% | -276.5% | -158.0% | -1,064.1% | -574.8% | -1,312.9% | -402.9% | -929.9% | -1,190.3% |
| Debt to Equity | 0.54x | 0.13x | 0.16x | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ovation Science Inc dividends
Ovation Science Inc has not paid dividends in the last 9 fiscal years.
Who owns Ovation Science Inc
- Insiders 23.04%
- Institutions 0.00%
- Public & others 76.96%
- Shares outstanding 38.4M
- Free float 33.2M
Ovation Science Inc company profile
- Company name
- Ovation Science Inc
- Ticker
- OVATF.US
- ISIN
- CA69016D1087
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 1003-1166 Alberni Street, Vancouver, BC, Canada, V6E 3Z3
- Phone
- 604 982 5700
- Website
- ovationscience.com
About Ovation Science Inc
Ovation Science Inc. engages in the production, sub-licensing, and sale of cannabis or hemp products in the United States. The company's patented skin delivery technology Invisicare, a patented polymer-based technology for topical and transdermal skin care products under the Ovation brand name. It also offers cannabis health and wellness products under the Invibe MD name; anti-aging products under the ARLO CBD name; and topical and transdermal creams and lotions with CBD, THC, and combinations, as well as hemp seed oil. The company was incorporated in 2017 and is headquartered in Vancouver, Canada. Ovation Science Inc. operates as a subsidiary of Skinvisible Pharmaceuticals, Inc.
Ovation Science Inc management
2- Mr. Terry H. HowlettPresident, CEO & Director · born 1948
- Ms. Joan Chypyha B.Sc., M.B.A.CFO & Director · born 1967